Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life
暂无分享,去创建一个
A. Brennan | M. Reed | R. Audisio | M. Bradburn | K. Cheung | K. Horgan | T. Chater | E. Herbert | S. Walters | A. Ring | S. Ward | J. Patnick | C. Holcombe | K. Collins | L. Wyld | M. Gosney | A. Thomson | J. Gath | K. Lifford | J. Morgan | M. Burton | T. Robinson | G. Holmes | T. Green | D. Revell | A. Edwards | Charlene Martin | K. Pemberton | M. Hatton | M. Winter | A. Shrestha | Juliet Wright | R. Simcock | A. Todd | J. Naik | R. Parmeshwar | Juliet E. Wright
[1] R. Audisio,et al. Age specific recruitment and retention to a large multicentre observational breast cancer trial in older women: The Age Gap Trial , 2020, Journal of geriatric oncology.
[2] R. Audisio,et al. Breast cancer surgery in older women: outcomes of the Bridging Age Gap in Breast Cancer study , 2020, The British journal of surgery.
[3] S. Walters,et al. Quality of life versus length of life considerations in cancer patients: A systematic literature review , 2019, Psycho-oncology.
[4] M. Reed,et al. Efficient development and usability testing of decision support interventions for older women with breast cancer , 2019, Patient preference and adherence.
[5] L. Esserman,et al. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents , 2018, JAMA surgery.
[6] M. Reed,et al. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer‐specific survival , 2018, The British journal of surgery.
[7] F. Mahoney,et al. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.
[8] Amy P Abernethy,et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.
[9] M. Reed,et al. Case‐mix analysis and variation in rates of non‐surgical treatment of older women with operable breast cancer , 2015, The British journal of surgery.
[10] K. Brain,et al. The information and decision support needs of older women (>75 yrs) facing treatment choices for breast cancer: a qualitative study , 2014, Psycho-oncology.
[11] I. Ellis,et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Gazet,et al. A randomised trial comparing tamoxifen vs. surgery in patients over the age of 70 with operable breast cancer--final results after 28 years of follow-up. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[14] I. Ellis,et al. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre , 2011, British Journal of Cancer.
[15] P. Ellis,et al. Breast cancer in older women: trials and tribulations. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).
[16] L. Husain,et al. Choices in cancer treatment: a qualitative study of the older women's (>70 years) perspective , 2008, Psycho-oncology.
[17] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[18] Stephen J. Clarke,et al. Nutritional Assessment in Cancer: Comparing the Mini-Nutritional Assessment (MNA) With the Scored Patient-Generated Subjective Global Assessment (PGSGA) , 2005, Nutrition and cancer.
[19] M. Reed,et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). , 2014, The Cochrane database of systematic reviews.
[20] P. Therasse,et al. Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Elledge,et al. Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.
[23] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[24] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[25] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[26] M. Lawton,et al. Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.
[27] M. Lawton,et al. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .
[28] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[29] Ross Camidge,et al. The European Organisation for Research and Treatment of Cancer , 2002 .
[30] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[31] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.